Loading clinical trials...
Loading clinical trials...
An Open-label Pilot Study to Evaluate the Safety and Efficacy of ADCT-301 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Myeloproliferative Neoplasms.
Conditions
Interventions
ADCT-301
Locations
1
United States
Duke University Health System
Durham, North Carolina, United States
Start Date
December 7, 2021
Primary Completion Date
November 3, 2022
Completion Date
November 3, 2022
Last Updated
May 12, 2023
NCT03520647
NCT06660368
NCT05143996
NCT05534620
NCT02143830
NCT05768932
Lead Sponsor
Gwynn Long, M.D.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions